17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery

You may be eligible if

• DISEASE CHARACTERISTICS:
• One of the following diagnoses:
• * Histologically or cytologically confirmed solid tumor\*
• * Unresectable disease
• * Hodgkin's or non-Hodgkin's lymphoma
• * Relapsed disease
• * Failed at least 1 prior therapy
• * Neoplastic cells are accessible through biopsy NOTE: \*Only patients with biopsy-accessible superficial tumors or lymphoma are eligible once the maximum tolerated dose has been determined
• No known standard therapy that is potentially curative or definitely capable of extending life expectancy exists
• No CNS metastases
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Absolute neutrophil count at least 1,500/mm\^3
• Platelet count at least 100,000/mm\^3
• Hemoglobin at least 9 g/dL
• Hepatic:
• Bilirubin no greater than 2 times upper limit of normal (ULN)
• AST no greater than 2.5 times ULN
• Alkaline phosphatase no greater than 2 times ULN (5 times ULN if liver involvement)
• Renal:
• Creatinine no greater than 1.25 times ULN OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No New York Heart Association class III or IV heart disease
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective nonhormonal contraception
• No uncontrolled infection
• No seizure disorder
• No history of serious allergic reaction to eggs
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• More than 4 weeks since prior immunotherapy
• More than 4 weeks since prior biologic therapy
• No concurrent immunotherapy
• No concurrent routine or prophylactic use of a colony-stimulating factor (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\])
• Chemotherapy:
• More than 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) and recovered from acute and reversible toxic effects
• No other concurrent chemotherapy
• Endocrine therapy:
• No concurrent birth control pills
• No concurrent steroids as anti-emetics
• Radiotherapy:
• More than 4 weeks since prior radiotherapy
• No prior radiotherapy to more than 25% of the bone marrow
• No prior radiopharmaceuticals
• No concurrent radiotherapy
• Surgery:
• Not specified
• Other:
• No concurrent 3A4 enzyme inhibitors (e.g., verapamil, erythromycin, miconazole, or ketoconazole)
• No concurrent investigational ancillary therapy
• No concurrent enrollment in another study involving a pharmacologic agent (e.g., drugs, biologics, immunotherapy approaches, or gene therapy) for symptom control or therapeutic intent